Hims & Hers Health Has a Range of Strategies It Can Pursue -- Market Talk

Dow Jones

May 07, 2025

1420 ET - Hims & Hers Health appears to have two potential strategies with a range of full-year revenue outcomes, Bank of America analysts say in a research note. If Hims grows its personalized semaglutide business, it could meet or beat the top end of its guidance, generating over $900 million in GLP-1 revenue, the analysts estimated. Such a strategy could reintroduce litigation risk, though, they added. Alternatively, if Hims reinvests more in its core business, the segment's trends could stabilize or accelerate though overall revenue could fall toward the low end of guidance, they said. If the company pursues both at the same time, it could outperform the analysts' estimates for $2.32 billion in full-year sales, they said. (kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

May 06, 2025 14:30 ET (18:30 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2533663056"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533663056\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533663056?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 02:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533663056","market":"fut","top_or_hot":-1,"title":"Hims & Hers Health Has a Range of Strategies It Can Pursue -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  1420 ET - Hims &amp; Hers Health appears to have two potential strategies with a range of full-year revenue outcomes, Bank of America analysts say in a research note. If Hims grows its personalized semaglutide business, it could meet or beat the top end of its guidance, generating over $900 million in GLP-1 revenue, the analysts estimated. Such a strategy could reintroduce litigation risk, though, they added. Alternatively, if Hims reinvests more in its core business, the segment's trends could stabilize or accelerate though overall revenue could fall toward the low end of guidance, they said. If the company pursues both at the same time, it could outperform the analysts' estimates for $2.32 billion in full-year sales, they said. (kelly.cloonan@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 06, 2025 14:30 ET (18:30 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Health Has a Range of Strategies It Can Pursue -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Health Has a Range of Strategies It Can Pursue -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-07 02:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  1420 ET - Hims &amp; Hers Health appears to have two potential strategies with a range of full-year revenue outcomes, Bank of America analysts say in a research note. If Hims grows its personalized semaglutide business, it could meet or beat the top end of its guidance, generating over $900 million in GLP-1 revenue, the analysts estimated. Such a strategy could reintroduce litigation risk, though, they added. Alternatively, if Hims reinvests more in its core business, the segment's trends could stabilize or accelerate though overall revenue could fall toward the low end of guidance, they said. If the company pursues both at the same time, it could outperform the analysts' estimates for $2.32 billion in full-year sales, they said. (kelly.cloonan@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 06, 2025 14:30 ET (18:30 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2533663056","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533663056","pubTimestamp":1746556200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1420 ET - Hims & Hers Health appears to have two potential strategies with a range of full-year revenue outcomes, Bank of America analysts say in a research note. If Hims grows its personalized semaglutide business, it could meet or beat the top end of its guidance, generating over $900 million in GLP-1 revenue, the analysts estimated. Such a strategy could reintroduce litigation risk, though, they added. Alternatively, if Hims reinvests more in its core business, the segment's trends could stabilize or accelerate though overall revenue could fall toward the low end of guidance, they said. If the company pursues both at the same time, it could outperform the analysts' estimates for $2.32 billion in full-year sales, they said. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc.","BK4196":"保健护理服务"},"translate_title":"Hims&Hers Health有一系列可以采取的策略——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":0.9},"content_text":"1420 ET - Hims & Hers Health appears to have two potential strategies with a range of full-year revenue outcomes, Bank of America analysts say in a research note. If Hims grows its personalized semaglutide business, it could meet or beat the top end of its guidance, generating over $900 million in GLP-1 revenue, the analysts estimated. Such a strategy could reintroduce litigation risk, though, they added. Alternatively, if Hims reinvests more in its core business, the segment's trends could stabilize or accelerate though overall revenue could fall toward the low end of guidance, they said. If the company pursues both at the same time, it could outperform the analysts' estimates for $2.32 billion in full-year sales, they said. (kelly.cloonan@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  May 06, 2025 14:30 ET (18:30 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}